Evidence map›Paper›PMID 41224798›Full record

ArticleScientific reports2025

Shikonin-copper coordination nanoparticles for enhanced antibacterial and antibiofilm activity against Staphylococcus aureus.

Yourang Jiang, Xueyong Tang, Ailin Wang, Hua Yang, Xue Jiang, Yinxin Zhang, Fanglu Lou

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yourang Jiang *Chongqing Clinical Research Center for Dermatology, Chongqing Key Laboratory of Integrative Dermatology Research, Key Laboratory of External Therapies of Traditional Chinese Medicine in Eczema, Department of Dermatology, Chongqing Traditional Chinese Medicine Hospital/The First Affiliated Hospital of Chongqing College of Traditional Chinese Medicine, Chongqing, 400011, China.
Xueyong Tang *Chongqing Clinical Research Center for Dermatology, Chongqing Key Laboratory of Integrative Dermatology Research, Key Laboratory of External Therapies of Traditional Chinese Medicine in Eczema, Department of Dermatology, Chongqing Traditional Chinese Medicine Hospital/The First Affiliated Hospital of Chongqing College of Traditional Chinese Medicine, Chongqing, 400011, China.
Ailin WangChongqing Clinical Research Center for Dermatology, Chongqing Key Laboratory of Integrative Dermatology Research, Key Laboratory of External Therapies of Traditional Chinese Medicine in Eczema, Department of Dermatology, Chongqing Traditional Chinese Medicine Hospital/The First Affiliated Hospital of Chongqing College of Traditional Chinese Medicine, Chongqing, 400011, China.
Hua YangChongqing Clinical Research Center for Dermatology, Chongqing Key Laboratory of Integrative Dermatology Research, Key Laboratory of External Therapies of Traditional Chinese Medicine in Eczema, Department of Dermatology, Chongqing Traditional Chinese Medicine Hospital/The First Affiliated Hospital of Chongqing College of Traditional Chinese Medicine, Chongqing, 400011, China.
Xue JiangChongqing Clinical Research Center for Dermatology, Chongqing Key Laboratory of Integrative Dermatology Research, Key Laboratory of External Therapies of Traditional Chinese Medicine in Eczema, Department of Dermatology, Chongqing Traditional Chinese Medicine Hospital/The First Affiliated Hospital of Chongqing College of Traditional Chinese Medicine, Chongqing, 400011, China.
Yinxin ZhangChongqing No.6 People's Hospital, Chongqing, 400060, China. 570130365@qq.com.
Fanglu LouChongqing Clinical Research Center for Dermatology, Chongqing Key Laboratory of Integrative Dermatology Research, Key Laboratory of External Therapies of Traditional Chinese Medicine in Eczema, Department of Dermatology, Chongqing Traditional Chinese Medicine Hospital/The First Affiliated Hospital of Chongqing College of Traditional Chinese Medicine, Chongqing, 400011, China. luckxiaoxin@163.com.

Funding

National Natural Science Foundation of China 82205133
6 · The paper itself

Abstract

Antimicrobial resistance (AMR) poses a critical global health challenge, with an estimated 1.27 million AMR-attributable deaths in 2019 and projections of 39 million cumulative deaths from 2025 to 2050, particularly driven by Staphylococcus aureus and methicillin-resistant strains (MRSA) that form robust biofilms conferring up to 1000-fold antibiotic tolerance and complicating hospital-acquired infections. Here, we report a green, one-pot synthesis of shikonin-copper nanoparticles (SCu NPs), employing shikonin (SK)-a naphthoquinone from Lithospermum erythrorhizon roots-as a dual chelator and stabilizer, without exogenous reductants or surfactants; density functional theory (DFT) computations guide the design, predicting thermodynamically favored 1:2 Cu(II): SK stoichiometry, yielding stable spherical nanoparticles (39.25 ± 3.24 nm) with preserved Cu(II) oxidation state, as validated by TEM, XPS, XRD, and UV-Vis spectroscopy. SCu NPs exhibit potent antibacterial activity against S. aureus ATCC 25,923, with minimum inhibitory and bactericidal concentrations (MIC/MBC) of 4/8 µg/mL-half those of SK (8/16 µg/mL)-and rapid bactericidal kinetics, reducing viability by 66% within 2 h; antibiofilm assays reveal concentration-dependent inhibition, achieving up to 89% biomass reduction at 32 µg/mL, outperforming SK, CuSO

Indexed as

Anti-Bacterial AgentsBiofilmsCopperMetal NanoparticlesNaphthoquinonesStaphylococcus aureusMethicillin-Resistant Staphylococcus aureusMicrobial Sensitivity TestsAnti-Bacterial AgentsCopperNaphthoquinonesshikoninAntibacterial activityAntibiofilm activityCopper nanoparticlesShikonin

Identifiers

PMID41224798
PMCPMC12612078

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.